Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

New Data on EMA401 in Model of Diabetic Neuropathy Presented at 21st Annual NEURODIAB Meeting

September 12, 2011 By Bio-Medicine.Org

MELBOURNE, Australia, September 12, 2011 /PRNewswire/ —

 

EMA401 Shown to Improve Nerve and Neurovascular Function

Spinifex Pharmaceuticals, an Australian pain drug development
company, today announces the presentation of new data from a study
of EMA401 in a model of diabetic neuropathy. EMA401 is an
angiotensin II type 2 (AT2) receptor antagonist currently in
clinical development for a number of neuropathic pain
indications.

The new data were presented at the 21st annual meeting of the
Diabetic Neuropathy Study Group of the European Association for the
Study of Diabetes, NEURODIAB, on the 11th September by Professors
Norman Cameron and Mary Cotter of the University of Aberdeen.

Diabetic neuropathy is a side effect of diabetes that is
characterized by the peripheral nerves not functioning properly.
Patients present with symptoms that include pain but can also
include sensory loss and reduced reflex. Diminished nerve
conduction velocities resulting from damage to the peripheral
nervous system have also been linked to other serious side effects
of diabetes such as ulcers of the feet and legs which can
ultimately lead to amputation.

In the new study, initiated by Spinifex Pharmaceuticals, EMA401
was shown to correct motor and sensory nerve conduction velocity
(NCV) in an established animal model of diabetes. EMA401 also
reduced pain and heat sensitivity and corrected sciatic nerve
nutritive blood flow. EMA401 was effective at a dose of 1 mg/kg/day
and no CNS side effects were observed, consistent with earlier
studies at this and higher doses.

Spinifex Pharmaceuticals CEO Tom McCarthy said: “The discovery
that AT2 receptor antagonists offer an innovative approach to the
treatment of neuropathic and inflammatory pain was originally made
by Professor Maree Smith at The University of Queensland and we
have good earlier data on the impact of EMA401 on neuropathic pain
in pre-clinical models. This new study we initiat

‘/>”/>

SOURCE

Related Articles Read More >

CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’
Blackrock's Utah array is a miniature array of electrodes for sensing brain signals
Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I

DeviceTalks Weekly.

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech